| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/15/2009 | US20090017043 Connective tissues growth factor antibodies |
| 01/15/2009 | US20090017042 Process for the determination of the primary structure of the messenger rna coding for the human recombinant endooligopeptidase a (heopa) [af217798] |
| 01/15/2009 | US20090017041 Monoclonal antibody |
| 01/15/2009 | US20090017040 Monoclonal antibody |
| 01/15/2009 | US20090017039 SP35 Antibodies and uses thereof |
| 01/15/2009 | US20090017038 Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods |
| 01/15/2009 | US20090017037 Human TIMP-1 Antibodies |
| 01/15/2009 | US20090017036 Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| 01/15/2009 | US20090017035 Human antibodies to human delta like ligand 4 |
| 01/15/2009 | US20090017034 inhibits thymic stromal lymphopoietin TSLP)-mediated lymphocyte stimulation; using these polypeptides as molecular weight markers that allow the estimation of the molecular weight of a protein or a fragmented protein |
| 01/15/2009 | US20090017033 Inhibiting receptor activated nuclear factor kappa beta ligand (RANKL); immunoregulation |
| 01/15/2009 | US20090017032 Mammalian cx3c chemokine antibodies |
| 01/15/2009 | US20090017031 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 01/15/2009 | US20090017030 Endothelial Cell Expression Patterns |
| 01/15/2009 | US20090017029 Methods and Compositions for Treating Ocular Disorders |
| 01/15/2009 | US20090017028 Antigen binding fragments (fab fragments) binds to a plurality of beta-chemokines; glomerulonephritis, scleroderrna, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis; antiinflammatory agents |
| 01/15/2009 | US20090017027 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/15/2009 | US20090017026 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/15/2009 | US20090017025 Combinations Comprising a CDK Inhibitor and a Growth Factor Antibody or Anti-Mitotic |
| 01/15/2009 | US20090017024 Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders |
| 01/15/2009 | US20090017023 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/15/2009 | US20090017022 Sulfatases and methods of use thereof |
| 01/15/2009 | US20090017021 Methods and compositions for inducing innate immune responses |
| 01/15/2009 | US20090017020 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| 01/15/2009 | US20090017019 Methods and compositions for modulating bmp-10 activity |
| 01/15/2009 | US20090017018 Uses of mammalian cytokine: related reagents |
| 01/15/2009 | US20090017017 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
| 01/15/2009 | US20090017016 Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
| 01/15/2009 | US20090017015 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| 01/15/2009 | US20090017014 Compositions and methods for the treatment of immune related diseases |
| 01/15/2009 | US20090017012 Methods of diagnosing and treating cancer |
| 01/15/2009 | US20090017011 Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis |
| 01/15/2009 | US20090017010 Novel artemis/dna-dependent protein kinase complex and methods of use thereof |
| 01/15/2009 | US20090017009 Method for the diagnosis and prognosis of malignant diseases |
| 01/15/2009 | US20090017008 Compositions and methods for altering bone density and bone patterning |
| 01/15/2009 | US20090016991 Rxr Antagonist Treatment Against Multiple Sclerosis |
| 01/15/2009 | US20090016989 Antibodies to human somatostatin receptor and methods of use |
| 01/15/2009 | US20090016988 Modified Pore-Forming Protein Toxins and Use Thereof |
| 01/15/2009 | US20090016968 Composition and method for prevention and treatment of type i diabetes |
| 01/15/2009 | US20090016967 Compositions and methods for the treatment of respiratory disorders |
| 01/15/2009 | US20090016965 Internal image antibodies for optical imaging and therapy |
| 01/15/2009 | US20090016963 Genes involved in neurodegenerative conditions |
| 01/15/2009 | US20090016961 Stem Cell Fusion Model of Carcinogenesis |
| 01/15/2009 | US20090016959 Drug delivery across the blood-brain barrier using polypeptides; neurological diseases; aprotinin |
| 01/15/2009 | CA2693717A1 Immunology treatment for biofilms |
| 01/15/2009 | CA2693677A1 Combination therapies employing gitr binding molecules |
| 01/15/2009 | CA2693616A1 Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| 01/15/2009 | CA2693611A1 Novel formulation |
| 01/15/2009 | CA2693455A1 An antibody specific for the tn antigen for the treatment of cancer |
| 01/15/2009 | CA2692977A1 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
| 01/15/2009 | CA2692933A1 Yersinia pestis antigens, vaccine compositions, and related methods |
| 01/15/2009 | CA2692786A1 Immunotherapy for hematological malignancies |
| 01/15/2009 | CA2692744A1 Apparatus and method for harvesting biologics from eggs |
| 01/15/2009 | CA2692689A1 Rapid generation of t cell-independent antibody responses to t cell-dependent antigens |
| 01/15/2009 | CA2692682A1 Methods and compositions useful in the treatment of mucositis |
| 01/15/2009 | CA2692681A1 Stable liquid formulation of the anti-cd20 antibody ofatumumab |
| 01/15/2009 | CA2692637A1 Treatment and diagnostic methods for fibrosis related disorders |
| 01/15/2009 | CA2692546A1 Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery |
| 01/15/2009 | CA2690317A1 Replication deficient influenza virus for the expression of heterologous sequences |
| 01/15/2009 | CA2680741A1 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 01/14/2009 | EP2014770A2 WNT-1 Iinduced secreted polypeptide WISP-2 |
| 01/14/2009 | EP2014679A1 KDR peptides and vaccines comprising the same |
| 01/14/2009 | EP2014678A2 KDR peptides and vaccines comprising the same |
| 01/14/2009 | EP2014677A1 A-33 related antigens and their pharmacological uses |
| 01/14/2009 | EP2014675A1 Compositions and methods for the treatment of immune related diseases |
| 01/14/2009 | EP2014303A2 APO-2L receptor agonist and CPT-11 synergism |
| 01/14/2009 | EP2014302A1 An antibody specific for the Tn antigen for the treatment of cancer |
| 01/14/2009 | EP2014301A1 Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/14/2009 | EP2014300A1 Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome |
| 01/14/2009 | EP2014298A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014279A1 Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| 01/14/2009 | EP2014180A1 Composition useful for the reduction of the cardivascular risk and foods that contain it |
| 01/14/2009 | EP2013621A1 ANTI-FACTOR XIIa THERAPY |
| 01/14/2009 | EP2013236A1 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk |
| 01/14/2009 | EP2013235A1 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| 01/14/2009 | EP2013227A1 Hiv-1 immunogenic compositions |
| 01/14/2009 | EP2012829A2 Method for producing viral vaccine and therapeutic peptide antigens |
| 01/14/2009 | EP2012826A2 Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases |
| 01/14/2009 | EP2012824A2 Uses and compositions for treatment of psoriasis |
| 01/14/2009 | EP2012822A2 Modified adenovirus hexon protein and uses thereof |
| 01/14/2009 | EP2012821A2 Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections |
| 01/14/2009 | EP2012820A2 Compositions and methods for treating anthrax lethality |
| 01/14/2009 | EP2012814A1 Methods of treating autoimmune diseases |
| 01/14/2009 | EP2012791A2 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors |
| 01/14/2009 | EP2012771A2 Nanoemulsion vaccines |
| 01/14/2009 | EP2012586A2 Uses and compositions for treatment of ankylosing spondylitis |
| 01/14/2009 | EP1751289B1 Tc-83-derived alphavirus vectors, particles and methods |
| 01/14/2009 | EP1751276B1 Vaccine comprising an attenuated pestivirus |
| 01/14/2009 | EP1659918B1 Antibodies directed to parathyroid hormone (pth) and uses thereof |
| 01/14/2009 | EP1609858B1 Method for detecting substrates or inhibitors for branched neutral amino acid transporters |
| 01/14/2009 | EP1549741B1 Novel endothelial cells, antibodies against said cells and use thereof |
| 01/14/2009 | EP1487486B1 Imidazoquinolineamines as adjuvants in hiv dna vaccination |
| 01/14/2009 | EP1423133B1 Treatment of muscular dystrophies and related disorders |
| 01/14/2009 | EP1390389B1 Cripto blocking antibodies and uses thereof |
| 01/14/2009 | EP1341810B1 Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type iii secretion pathway of a gram-negative bacteria. |
| 01/14/2009 | EP1331270B1 Novel recombinant feline herpesvirus 1 and polyvalent vaccine with the use of the same |
| 01/14/2009 | EP1297142B1 Dual specificity antibodies and methods of making and using |
| 01/14/2009 | EP1283057B1 Cell proliferation inhibitors |
| 01/14/2009 | EP1233948B1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |